Skip to main content

Table 1 Baseline characteristics of the patients by treatment group.

From: Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir

  Initiating abacavir Initiating tenofovir P a
N 28 22 -
Characteristics at study entry    
   Male, (%) 71 91 0.088
   Age (yrs), median (IQR) 35 (32-43) 40 (35-46) 0.042
   Time on ART (yrs)b, median (IQR) 2.5 (0.75-5.0) 1 (0.55-3.25) 0.463
   ART received during the study period    
PI based (%) 32 27 0.477
NNRTI based (%) 68 73 0.477
   CD4 cell count (cells/mm3), median (IQR) 260 (152-357) 200 (150-252) 0.072
   Lipodystrophy (%) 3.5 13.6 0.308
   Prior cardiovascular disease (%) 0 0 -
   Hypertension (%) 7.1 4.5 0.591
   Systolic blood pressure (mmHg), median (IQR) 124 (112-130) 119 (111-140) 0.747
   Diastolic blood pressure (mmHg), median (IQR) 74 (68-85) 72 (63-83.5) 0.518
   Diabetes (%) 0 0 -
   Current smokers (%) 75 81 0.411
   Lipid-lowering drugs (%) 3.6% 4.5% 0.691
   Total cholesterol (mg/dL), median (IQR) 173 (134-189) 165 (126-201) 0.822
   LDL-cholesterol (mg/dL), median (IQR) 99 (84-122) 94 (72-126) 0.747
   HDL-cholesterol (mg/dL), median (IQR) 38 (33-46) 42 (30-45) 0.792
   Triglycerides (mg/dL), median (IQR) 115 (80-159) 112 (89-179) 0.591
   Framingham risk score, median (IQR) 6.0 (1.5-10) 7.5 (3.3-13.3) 0.417
   Framingham risk at 10 yrsc, median (IQR) 2 (1-6) 3.5 (1-13) 0.512
   Hepatitis C-virus coinfection (%) 53 45 0.577
   eGFRd (ml/min*1.73m2), median (IQR) 87.1 (78.3-107.1) 85.8 (67.0-93.2) 0.120
   hsCRP levels (mg/L), median (IQR) 1.5 (0.5-3.2) 1.7 (0.6-3.6) 0.845
   IL-6 levels (ρg/mL), median (IQR) 0.8 (0.3-2.7) 2.7 (0.8-5.6) 0.079
   sVCAM-1 (ηg/mL), median (IQR) 818 (524-1088) 889 (778-1354) 0.315
   sICAM-1 (ηg/mL), median (IQR) 499 (370-955) 485 (444,-) 0.840
   PAI-1 (ηg/mL), median (IQR) 2.6 (1.5-7.1) 2.8 (1.4-4.3) 0.710
  1. aMann-Whitney U test or Chi-square test as appropriate. bOnly for preteated patients. cFor coronary heart disease outcomes (myocardial infarction and coronary death). dGlomerurar filtration rate estimated by Cockroft-Gault formula. IQR, interquartile range; ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; hsCRP, high sensitivity C reactive protein; IL-6, interleukin-6; sVCAM-1, vascular cell adhesion molecule-1; sICAM, intercellular adhesion molecule-1; PAI-1, plasminogen activator inhibitor-1.